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Background: Robust markers that predict prognosis and detect early treatment response in malignant pleural mesothelioma
(MPM) would enhance patient care.
Methods: Consecutive patients with MPM who were considered fit for first-line chemotherapy were prospectively recruited.
Patients of similar performance status opting for best supportive care were included as a comparator group. Baseline and interval
CT, PET-CT and serum markers (mesothelin, fibulin-3 and neutrophil–lymphocyte ratio (NLR)) were obtained, and patients
followed up for a minimum 12 months.
Findings: Seventy-three patients were recruited (58 chemotherapy/15 comparator arm). Baseline TGV (total glycolytic volume on
PET-CT) was an independent predictor of worse overall survival (OS) (P¼ 0.001). Change in interval TGV(baseline/after two cycles
of chemotherapy) did not predict OS or chemotherapy response on CT. Baseline NLRo4 was an independent predictor of better
OS (median survival 453 (IQR 272–576) days vs NLRX4, 257 (IQR 147–490), P¼ 0.002). Although baseline serum mesothelin did not
predict OS, a falling level at 8 weeks significantly predicted longer time to progression (TTP) (Po0.001).
Interpretation: Neutrophil–lymphocyte ratio and baseline TGV predict prognosis in malignant pleural mesothelioma (MPM), but
PET-CT is unhelpful in monitoring chemotherapy response. Serum mesothelin is a useful early treatment response marker when
measured serially during chemotherapy and may have a role in evaluating patients’ treatment response.
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Malignant pleural mesothelioma (MPM) remains a universally
fatal neoplasm with a median life expectancy of 9–14 months
following diagnosis (Yates et al, 1997; Chapman et al, 2009).
In 2008, the National Institute for Health and Care Excellence
(NICE) recommended the use of chemotherapy with pemetrexed
and cisplatin for the palliative treatment of mesothelioma in
England and Wales and this remains the first-line chemotherapy
regimen of choice in patients with good performance status
(Vogelzang et al, 2003; NICE (2008), HTA No. 135).
With variable clinical responses to pemetrexed and cisplatin in
MPM and common associated adverse effects (particularly nausea,
fatigue and haematological toxicity) (Vogelzang et al, 2003),
patient selection for treatment, individualised prognostic informa-
tion at diagnosis and early disease response evaluation are
important areas about which little is currently established.
The most widely used method of chemotherapy response
evaluation for MPM in a clinical trial setting is serial CT scanning,
using the modified RECIST criteria (Nowak, 2005). Although the
modified RECIST method has been shown to correlate with
survival in patients receiving chemotherapy, it does not make a full
assessment of the circumferential growth pattern of MPM, and
high levels of interobserver variability have been reported (Armato
et al, 2004; Byrne and Nowak, 2004). Volumetric assessment of CT
may be superior to the modified RECIST (Guntulu et al, 2010), but
both methods are labour intensive and probably not of universal
applicability to clinical practice.
Metabolic imaging with PET-CT using a composite output
value incorporating 18FDG uptake and tumour volume (total
glycolytic volume (TGV)), serum biomarkers including mesothelin
and fibulin-3 and measures of systemic inflammation such
as the NLR have all been the subject of preliminary research as
markers of prognosis or treatment response in MPM (Francis et al,
2007; Grigoriu et al, 2008; Creaney et al, 2010; Kao et al, 2010;
Nowak et al, 2010; Veit-Haibach et al, 2010; Pass et al, 2012;
Creaney et al, 2014).
The SWAMP trial was designed to systematically and
prospectively examine the value of serum biomarkers, NLR and
TGV measured by PET-CT, with correlation of markers to disease
response, survival and quality of life.
MATERIALS AND METHODS
Study design. Multicentre prospective observational parallel
cohort study evaluating biomarkers and novel imaging techniques
as predictors of mesothelioma tumour response to first-line
chemotherapy (pemetrexed and cisplatin/carboplatin). The trial
incorporated a self-selecting ‘comparator’ group of patients of
similar performance status who declined chemotherapy after
consultation with an oncologist. Randomisation to a ‘no-
chemotherapy’ arm was considered unethical by the investigators
on the basis of the previous published data and NICE guidance.
Study setting and enrolment. Subjects were screened from
normal clinical practice following discussion in the regional
mesothelioma multidisciplinary team meeting. Patients were
enrolled from oncology clinics of seven hospitals in the South
West of the United Kingdom (North Bristol NHS Trust, University
Hospitals Bristol NHS Foundation Trust, Royal United Hospital
Bath, Gloucestershire Hospitals Foundation Trust, Taunton and
Somerset NHS Foundation Trust, Great Western NHS Foundation
Trust Swindon and Weston General Hospital). Inclusion criteria
were histologically proven MPM and sufficient performance status
and medical history to consider first-line chemotherapy. Patients
were excluded if the estimated life expectancy was o3 months,
there was previous or planned debulking surgery or there was no
measurable pleural thickening on baseline CT imaging to allow
assessment of the primary end point (Supplementary Information
1 online).
Standard care and baseline tests. Patients had a staging CT
within 12 weeks of trial entry before any chemotherapy and
underwent a standard oncology clinical assessment. Patients who
opted for chemotherapy received pemetrexed and cisplatin or
carboplatin, up to a maximum of six cycles at 21-day intervals
according to a standardised regimen (Supplementary Information
2 online). Patients opting for best supportive care without
chemotherapy were offered inclusion in the comparator arm.
Trial interventions. Consented patients underwent a PET-CT
scan at baseline and again after two cycles of chemotherapy (or a 6-
to 8-week interval in the non-chemotherapy comparator arm).
Positron emission tomography-computed tomography methodol-
ogy is given in Supplementary Information 3 online. A standard
thorax and abdomen CT was performed following three cycles of
chemotherapy, and at 4, 9 and 12 months after recruitment.
Neutrophil–lymphocyte ratio (NLR) was recorded at baseline.
Blood was stored for mesothelin and fibulin-3 assay at recruitment,
after two cycles and at completion of chemotherapy (or equivalent
timings in the comparator arm). All patients were followed
up for a minimum of 12 months or until death, with recording of
clinical data. All scans were double reported by consultant
radiologists who were blind to clinical data. Health-related quality
of life (HRQoL) data was recorded at 5 time-points (baseline, 6
weeks, 4 months, 12 months and 18 months). Three HRQoL
questionnaires were used: the EQ-5D, EORTC QLQ-C30 and
EORTC LC13. Health-related quality of life data is presented
separately (Arnold et al, 2015).
Trial outcomes
Primary end point. The primary end point was defined as the
difference in time to progression (TTP) on serial CT scans. This
was compared between patients demonstrating a metabolic
response (MR) to chemotherapy on interval PET-CT after two
cycles of chemotherapy vs those demonstrating no MR.
Time to progression: TTP was defined by the modified RECIST
criteria as the time to a 20% or greater increase in linear
measurement of pleural tumour compared with baseline on CT
(Nowak, 2005).
Metabolic responder: MR was defined as a decrease in TGV on
interval PET-CT of 30% or more (Francis et al, 2007).
Secondary end points. The secondary outcomes were:
(1) Relationship between overall survival (OS), baseline PET-CT
parameters, MR on PET-CT (TGV) and baseline and interval
biomarkers.
(2) Correlation of interval biomarkers and PET-CT parameters to
TTP on CT.
Data analysis and preparation of the manuscript. A written
analysis plan, including pre hoc decisions on subgroups to be
analysed, was finalised by the trial steering committee before data
analysis. As per a prespecified analysis plan, those subjects who did
not receive both PET-CT scans, at least two cycles of chemother-
apy and a 2-month CT scan, were excluded from the primary end-
point analysis (as these parameters were all necessary for the
primary outcome measurement) but included in all other analyses.
The comparator group was used to examine the interval
behaviour of the radiographic and biomarkers examined in the
absence of systemic anticancer treatment.
Statistical analysis and sample size. The study was powered to
examine the association between MR and TTP status using
standard tests of association (Pearson’s w2 test of association,
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Fisher’ exact test). A minimum sample size of n¼ 58 in the
chemotherapy arm would be needed to detect a medium to large
effect size (odds ratio¼ 6) with 80% power using standard levels of
significance (a¼ 0.05) assuming uniform marginal probabilities.
The nonparametric Mantel–Cox log-rank test was used in a
Kaplan–Meier survival analysis to investigate the relationship
between potential biomarkers and OS. Censoring (due to death and
loss to follow-up) occurred at the time of data analysis with all
patients receiving a minimum of 12 months follow-up. Censored
patients are marked on all Kaplan–Meier curves presented. Cox
proportional hazards survival analysis was used to evaluate the
independent and joint multivariate effects of histological subtype
and baseline measures of TGV and neutrophil lymphocyte ratio on
OS. Data imputation for any missing values was not used.
Trial funding and support. The trial was funded through an
unrestricted education grant from the Cobalt Appeal Fund,
Cheltenham, UK.
Ethical approval and registration. Ethical and regulatory
approval for the study was obtained before recruitment com-
menced (UK REC Reference: 08/H0102/46). The trial was
registered in the national portfolio (UKCRN ID: 8450).
RESULTS
Patients. Seventy-three patients were recruited between Septem-
ber 2008 and December 2011. Patient enrolment, withdrawal and
primary end-point acquisition is summarised in Figure 1. Median
time from diagnosis to trial entry was 11 days (IQR 7–44). Of the
enrolled patients, 63 (86%) were male, and 50 (68%) had
epithelioid subtype histology. Baseline characteristics of all enrolled
patients are summarised in Table 1.
Clinical outcomes. Median survival from consent to death in the
chemotherapy group was 368 days (IQR 195–526) and in the
comparator group 325 days (IQR 176–458) equating to 12.3 and
10.8 months, respectively (P¼ 0.401). The number of chemother-
apy cycles delivered was determined by oncologists using standard
clinical assessment without access to serum biomarkers or PET-CT
TGV. Eighty-seven per cent of patients in the chemotherapy group
received two or more cycles, 64% received four or more cycles and
36% received six cycles.
Histological subtype was a strong independent predictor of
survival in the group as a whole, with epithelioid histology
associated with a median survival of 456 (IQR 303–609) days,
Patients consented 
Chemotherapy arm = 58 
Comparator arm = 15 
Baseline PET–CT obtained 
Chemotherapy arm = 51 
Comparator arm = 14 
Primary end point obtained 
Chemotherapy arm = 41 
Comparator arm = 13 
Patients without baseline PET–CT 
Chemotherapy arm =7 (4 withdrew from
trial, 2 unable to tolerate scans, 1 too 
unwell)  
Comparator arm = 1  (unable to tolerate
scans)  
Patients without interval PET–CT or CT  
Chemotherapy arm =10  (3 only 1 cycle 
of chemo, 1 chemo delayed, 1 unable to 
tolerate scans, 2 too unwell, 1 died, 2 
corrupted scans) 
Comparator arm = 1  (too unwell) 
Figure 1. Patient enrolment, withdrawal and primary end point acquisition.
Table 1. Baseline patient characteristics (including all enrolled
patients)
Chemotherapy
arm
Comparator
arm
Number of patients 58 15
Age: median (IQR) 69 (65–73) 77 (68–80)
Male:female 52:6 11:4
Histology
Epithelioid 39 (67%) 11 (73%)
Biphasic 4 (7%) 0 (0%)
Sarcomatoid 15 (26%) 4 (26%)
Mode of biopsy
CT guided 24 (41%) 8 (53%)
LAT 19 (33%) 5 (33%)
VATS 15 (26%) 2 (13%)
WHO PS
0 17 (29%) 2 (13%)
1 37 (64%) 11 (73%)
2 4 (7%) 2 (13%)
Talc pleurodesis before trial entry 21 (36%) 6 (40%)
Body mass index (BMI), mean (SD) 26.5 (3.3) 24.5 (3.6)
CT IMIG TMN stage
I 7 (12%) 1 (7%)
II 4 (7%) 1 (7%)
III 28 (48%) 6 (40%)
IV 19 (33%) 7 (47%)
Abbreviations: BMI¼body mass index; CT¼ computed tomography; IMIG¼ International
Mesothelioma Interest Group; IQR¼ interquartile range; LAT¼ limited axillary thoracotomy;
PS¼performance status; TMN¼ tumour node metastasis; VATS¼Video-assisted thoraco-
scopic surgery; WHO, World Health Organisation. Patient characteristics at baseline
(including all enrolled patients).
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compared with 197 (IQR 155–239) days in patients with non-
epithelioid histology (HR 0.17; 95% CI: 0.08–0.35; w2¼ 23.10;
d.f.¼ 1; Po 0.001; see Figure 2).
In patients receiving chemotherapy, 13% had a partial response,
41% stable disease and 46% progressive disease on CT scan by the
modified RECIST criteria after three cycles of chemotherapy.
Overall survival in chemotherapy patients with progression on CT
was 311 (IQR 177–458) days compared with 520 (IQR 291–584)
days in patients with CT-stable or -responsive disease. In the
comparator group, 86% had progressive disease and 14% stable
disease on CT at the equivalent time point with OS of 270 (IQR
177–458) days given disease progression and 625 (IQR 398–792)
days given disease stability.
Primary end point. Forty-one patients in the chemotherapy
group were included in the primary end point analysis. Thirty-
three out of 41 (80%) were classified as metabolic responders on
interval PET-CT (30% or greater fall in TGV). The median fall in
TGV in the chemotherapy group was 60%. There was no
significant difference between the MR and non-MR group in
TTP on interval CT at 2 months (after three cycles of
chemotherapy) (P¼ 0.429) or 4 months (P¼ 0.703). There
remained no significant difference in TTP independent of
histological subtype and when considering an alternative fall in
TGV of 60% or 70% in the definition of MR.
Median OS was not significantly higher in the MR group (456
(IQR 254–657) days) compared with the non-MR group (401
(IQR166–635) days) (P¼ 0.362) (see Figure 3).
Secondary end points
Radiographic markers. Higher values of all baseline PET-CT
parameters were significantly associated with shorter survival.
Considering a division at the median TGV of 1800, in the
chemotherapy group, patients with a baseline TGVX1800 had a
significantly shorter median survival of 266 (IQR 180–479) days
compared with 456 (IQR 266–653) days in patients with TGV
o1800 (HR 3.00; 95% CI: 1.53–5.88; w2¼ 13.53; d.f.¼ 1;
P¼ 0.001). Total glycolytic volume was independently predictive
of survival in a multivariable Cox proportional hazards model
including histological subtype (Po0.001). Data are given in online
Supplementary Information 4. Total glycolytic volume fell between
baseline and the 6-week PET-CT in 38 out of 41 (93%)
chemotherapy patients and 2 out of 13(15%) comparator patients
for whom interval PET-CT scans were available (see Figure 4).
Percentage change in TGV was not significantly associated with
survival (P¼ 0.726) or TTP at any time point.
Among all patients undergoing a PET-CT scan at baseline, 26
out of 63 (41%) had received talc pleurodesis before trial entry.
Baseline PET-CT parameters were not significantly different
between patients with and those without prior talc pleurodesis.
Of the chemotherapy patients who underwent interval PET-CT
scanning following two cycles of chemotherapy, 17 out of 41 (41%)
had undergone talc pleurodesis. There was no significant difference
in change in SUVmax (P¼ 0.517) or TGV (P¼ 0.229) between
those with and without prior talc pleurodesis. Data are given in
Supplementary Information 5 online. The primary outcome was
unchanged by the exclusion of patients who had received prior talc
pleurodesis.
Biomarkers
Neutrophil–lymphocyte ratio: In the whole group, median NLR
at baseline was 4.0 (IQR 3.1–6.4). Neutrophil–lymphocyte ratio did
not differ significantly between histological subgroups (P¼ 0.40).
An NLR o4.0 was a strong predictor of better survival
(chemotherapy group: NLRo4.0, median survival 453 (IQR 272–
576) days vs NLRX4, 257 (IQR 147–490) (HR 0.38; 95% CI: 0.20–
0.71; w2¼ 9.28; d.f.¼ 1; P¼ 0.002) as shown in Figure 5. The same
was true of the comparator group and was true in a multivariable
Cox proportional hazards model including histological subtype
and TGV; NLR was an independent predictor of OS (P¼ 0.01).
Baseline NLR also significantly predicted TTP in the whole
group and chemotherapy subgroup.
Serum mesothelin: Median serum mesothelin was 4.2 nM (IQR
2.65–9.88) in patients with epithelioid subtype histology and
1.36 nM (IQR 0.78–1.92) with non-epithelioid histology (Po0.001).
In the chemotherapy group, serum mesothelin at baseline
was not significantly associated with survival when considering a
median division (P¼ 0.196).Baseline mesothelin was positively
correlated with disease burden on initial CT using the modified
RECIST criteria (Spearman’s rank correlation coefficient¼ 0.446
(P¼ 0.002).
A falling mesothelin level between baseline and 6–8 weeks
(after two cycles of chemotherapy) was significantly associated
with longer TTP (Po0.001). A falling mesothelin level between
baseline and completion of chemotherapy (15–17 weeks) was
significantly associated with longer OS (481 days (IQR 192–525)
compared with those with a rising level (293 days (IQR 204–493)
(HR 0.46; 95% CI: 0.22–0.93; w2¼ 4.66; d.f.¼ 1; P¼ 0.031)
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Figure 2. Survival (days from trial entry to death) comparing epithelioid
and non-epitheliod histological subtypes among all enrolled patients
(n¼73).
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Figure 3. Survival in chemotherapy patients (who were included in the
primary end point analysis n¼ 41), classified as metabolic responders
(X30% reduction in TGV) and non-responders (o30% fall in TGV).
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(Table 2, Figure 6 and Supplementary Information 6online).
Sensitivity analysis, in which patients with a low mesothelin
(o1 nM) level at baseline were included and excluded, did not alter
these results, neither did defining thresholds for a rising or falling
mesothelin.
Fibulin-3: Considering chemotherapy and comparator patients
together, baseline median plasma fibulin-3 was 21.17 ngml 1
(IQR 13.46–34.41). Higher baseline plasma fibulin-3 was observed
in patients with epithelioid histology when compared with non-
epithelioid histology, and in the group as a whole, higher levels
were significantly associated with longer survival when a median
split was used (P¼ 0.044). However, survival differences were not
observed in either subgroup when epithelioid and non-epithelioid
subjects were analysed separately. Interval change in fibulin-3 was
not associated with survival (P¼ 0.972) or TTP at 2 months
(P¼ 0.288) or 4 months (P¼ 0.57). Fibulin-3 did not prove useful
in predicting response to treatment.
DISCUSSION
This is the first prospective, cohort study of patients with newly
diagnosed MPM receiving national guideline-driven chemotherapy
or best supportive care within the United Kingdom, to examine the
utility of PET-CT parameters, NLR and serum mesothelin in
prognostication and treatment response evaluation. Our results
have demonstrated that PET-CT at baseline predicts prognosis, as
does NLR, but these data do not support the use of PET-CT as a
tool to predict treatment response in mesothelioma.
It is notable that chemotherapy with pemetrexed and cis/
carboplatin was well tolerated in this series, with 64% patients who
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Chemotherapy
patients
Comparator
patients
% Change in TGV
Figure 4. Percentage change in TGV between baseline and 6-week PET-CT scan in comparator (n¼ 13) and chemotherapy (n¼ 41) patients for
whom interval PET-CT scans were available.
0 200 400 600 800 1,000
0
20
40
60
80
100
Patients at risk:
P = 0.002
Survival (days)
Pe
rc
e
n
ta
ge
 
su
rv
iv
a
l
NLR4
NLR < 4
NLR4
NLR < 4
Days: 0 200 400 600 800
26172526
27 916 3 2
Figure 5. Survival in days from trial entry to death in chemotherapy
patients with NLR o4 and NLRZ4 (all chemotherapy patients with
baseline NLR available are included, n¼53).
Table 2. Time to progression on CT in chemotherapy patients
with falling or stable mesothelin compared with rising
mesothelin at 6–8 weeks
Time point
CT modified
RECIST
report
Fall or stable
serum
mesothelin
Number (%)
Rise in
serum
mesothelin
Number (%)
Significant
difference
7–9 weeks (after three cycles)
Progression 5/20 (25%) 15/25 (60%) P¼0.002
No progression 15/20 (75%) 10/25 (40%) OR 7.50 (2.15–26.18)
15–17 weeks (after chemo)
Progression 6/20 (30%) 18/25 (72%) Po 0.001
No progression 14/20 (70%) 7/25 (28%) OR 15.71 (3.22–71.41)
Abbreviations: CT¼ computed tomography; OR¼odds ratio; RECIST¼Response Evalua-
tion Criteria In Solid Tumours. All chemotherapy patients with interval CT and interval
mesothelin data available are included, n¼ 45.
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opted to have treatment receiving four or more cycles. Quality of
life data from this series is published separately in the same issue of
this journal (Arnold et al, 2015).
We have demonstrated that PET-CT parameters strongly and
independently predict survival in patients with MPM when
measured at baseline. A TGV greater than the median (1800) in
patients receiving chemotherapy is associated with a median
survival of 9 months, compared with 16 months when the TGV is
o1800. In this study, a fall in TGV after two cycles of
chemotherapy was not of prognostic value, after removing those
who had had a talc pleurodesis. Therefore, the routine use of serial
PET-CT in treatment response monitoring is not indicated.
Recent studies have also demonstrated an association between
baseline PET-CT parameters and survival. Nowak et al (2010)
examined prognostic markers in 89 patients with MPM under-
going a range of management strategies and found TGV greater
than the median to predict worse survival in patients with non-
sarcomatoid histology but that sarcomatoid subtype was the
strongest predictor of poor survival. Lee et al (2010) examined a
similar semiquantitative volume-based PET-CT parameter, the
total lesion glycolyis (TLG) in 13 patients undergoing surgery or
palliative chemotherapy, demonstrating good performance in
predicting TTP on CT.
Two previous published studies have scrutinised volume-based
semiquantitative analysis of serial PET-CT scans as an early
treatment response indicator in MPM. Francis et al (2007)
performed PET-CT with TGV in 20 patients receiving cisplatin
and gemcitabine, before and after the first cycle of chemotherapy,
and demonstrated a significantly greater fall in TGV in seven
patients with a partial response on CT compared those with CT
stable disease in addition to an association between percentage
change in TGV and improved survival. Most recently, Veit-
Haibach et al (2010) examined PET-CT with TLG in 41 patients
receiving either first- or second-line chemotherapy (seven patients
having undergone prior surgical management), reporting a
significant association between percentage fall in TLG after three
cycles of chemotherapy and improved survival.
In our series, TGV fell in 93% of patients receiving
chemotherapy and increased in 85% of comparator patients at 6
weeks, but MR, absolute or percentage change in TGV did not
predict TTP on CT or OS. The particularly robust radiographic
processes that were applied in this study suggest that this is a true
finding. The most plausible explanation is that an early MR to
chemotherapy is not sustained or translated into pleural tumour
stability as measured by interval CT. It is now recognised that
chemotherapeutic agents cause a transient change in glucose
metabolism within some tumour cells, resulting in reduced FDG
uptake in an effect known as ‘stunning’, with an unknown duration
of persistence (Engles et al, 2006). Stunning is one potential
explanation for reduced measured PET-CT parameters without
correlation to sustained treatment response or survival.
An NLRo4 strongly and independently predicts better survival
and progression-free survival in our study patients in both the
chemotherapy and comparator groups. There was nearly 7 months
greater median survival in the low baseline NLR patients when
considering the chemotherapy group.
Systemic inflammation in patients with malignancy is con-
sidered to reflect the cytokine profile produced both by the tumour
and as a component of the host response to it. Increased levels of
systemic inflammation has been shown to correlate to worse
survival and poor response to treatment in a number of solid organ
tumours (Proctor et al, 2010; Roxburgh and McMillian, 2010).
Increased NLR has been specifically evaluated in non-small-cell
lung cancer and colorectal carcinoma and shown to be an
independent predictor of poor prognosis (Walsh et al, 2005;
Sarraf et al, 2009). There is evidence that the production of
proinflammatory cytokines by mesothelioma cells is a major
driving force for tumour progression (Fitzpatrick et al, 1995) and
immunotherapy; targeting aspects of the inflammatory response to
MPM may form an important component of future therapeutic
strategies. Neutrophil–lymphocyte ratio has been studied retro-
spectively by Kao et al (2010, 2011) in two series of patients with
MPM receiving systemic therapy and those undergoing EPP with a
lower NLR (o5) independently associated with improved survival.
Pinato et al (2012) further performed an analysis of the prognostic
value of NLR in a retrospective series of 171 patients diagnosed
over an 18-year period, finding a high NLR (45) to be a stronger
baseline predictor of survival than patient performance status. The
independent association of NLR with survival was further
demonstrated in a retrospective study of 910 patients who received
surgery, chemotherapy or best supportive care (Linton et al, 2014).
Ours is the first prospective series of mesothelioma patients
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Figure 6. Change in serum mesothelin (nM) between baseline and 6–8 weeks in the comparator (n¼15) and chemotherapy (n¼46) groups
(all patients with serial mesothelin results available are included).
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undergoing uniform clinical management to demonstrate the
prognostic value of this clinically accessible marker at baseline. The
optimal NLR cutoff value requires further evaluation in a large
prospectively collected cohort.
Mesothelin is a cell adhesion glycoprotein that is present on the
surface of mesothelial cells and is overexpressed in several
malignancies, including mesothelioma (Creaney and Robinson,
2005). The diagnostic value of serum mesothelin is limited by a
lack of specificity and low or negative results in patients with non-
epithelioid histology (Hooper et al, 2013), but two previous studies
have suggested its utility in monitoring disease response to
treatment. Creaney et al (2010) studied serial mesothelin levels
in 55 patient receiving two possible chemotherapy regimens and
demonstrated that percentage change between baseline and
completion of chemotherapy correlated to survival and that
patients with partial response on CT were more likely to have a
falling mesothelin. Grigoriu et al (2008) measured serial serum
mesothelin in 40 patients undergoing experimental intrapleural
gene therapy, demonstrating significantly shorter OS in patients
with a 10% or greater increase in mesothelin between baseline and
the end of treatment compared with those with stable values.
In our study, we showed a fall in serum mesothelin between
baseline and following two cycles of chemotherapy occurred in
44% of patients and significantly predicted stability on CT at 2 and
4 months. A falling level at completion of chemotherapy is
significantly associated with longer survival. For a patient experien-
cing troublesome side effects from chemotherapy, early predictive
information from serial serum mesothelin might usefully contribute
to clinical decision making and should be the subject of further study.
Fibulin-3 is a further cell-adhesion glycoprotein that is
expressed by condensing mesenchyme and can be measured in
plasma and pleural fluid by ELISA. A series published in 2012
presented excellent diagnostic accuracy in identifying MPM from
selective cohorts of asbestos exposed and healthy individuals, as
well as those with non-MPM malignancy, using a plasma fibulin-3
cutoff of 46 ngml 1 (Pass et al, 2012). Plasma levels were seen to
fall following cytoreductive surgery, suggesting a place in treatment
response monitoring. Recently, Creaney et al (2014) demonstrated
an association between higher pleural fluid fibulin-3 and reduced
survival, which may have been confounded by higher levels of the
biomarker in non-epithelioid effusions. Plasma fibulin-3 was
shown to have poor diagnostic sensitivity and no significant
association with prognosis or histology. Plasma fibulin-3 levels
measured in our series were comparable with those reported by
Creaney et al (2014) but considerably lower than those reported by
Pass et al (2012), with just 5 out of 63 (8%) having a level above the
proposed diagnostic cutoff. An apparent association between higher
levels of plasma fibulin-3 and longer survival in the current series is
likely to be explained by the confounding effect of histological
subtype. No association between interval change in fibulin-3 and
TTP or OS was seen. In summary, in this data set there appears to be
no role for fibulin-3 as a marker of treatment response.
Despite not being a randomised study, the SWAMP trial has
several strengths. Radiographic and clinical assessments were
robust with double reporting of all CT and PET-CT scans. Only
patients with a histological diagnosis of mesothelioma were
recruited, while many similar studies have accepted a cytological
diagnosis. This resulted in one of the largest groups of non-
epithelioid histology patients to have been prospectively recruited
to a trial of prognostic and treatment response markers. There was
no loss to follow-up such that survival data is complete.
There are also a few study limitations that need to be
highlighted. First, because of time and financial restraints, we did
not manage to recruit the number of patients identified in our
original power calculation. In addition, often because of patient
deterioration, only 41 out of 58 chemotherapy patients were
included in the primary end point analysis. Although this is one of
the largest mesothelioma studies of its kind, the small patient
numbers raise the possibility of type II errors with the secondary
outcomes and further studies in these areas would be beneficial,
perhaps with more frequent biomarker assessments.
In summary, NLR is readily available in clinical practice and
could assist clinicians when evaluating patients overall prognosis. It
may be a useful minimisation factor when setting up further
randomised clinical trials in mesothelioma. There appears to be no
role for routine interval PET-CT scanning in patients undergoing
chemotherapy; however, change in serum mesothelin could be an
indicator of treatment response and warrants further study. It
might also be useful if a future study attempted to split patients
into three categories (rising, falling and stable mesothelin), which
was not explored here because of study size. If mesothelin was
monitored regularly throughout treatment, it might have the
potential to assist oncologists in evaluating response.
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